Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Molecular imaging of aberrant crypt foci in the human colon targeting glutathione S-transferase P1-1.

Muguruma N, Okamoto K, Nakagawa T, Sannomiya K, Fujimoto S, Mitsui Y, Kimura T, Miyamoto H, Higashijima J, Shimada M, Horino Y, Matsumoto S, Hanaoka K, Nagano T, Shibutani M, Takayama T.

Sci Rep. 2017 Jul 26;7(1):6536. doi: 10.1038/s41598-017-06857-x.

2.

The different pathogeneses of sporadic adenoma and adenocarcinoma in non-ampullary lesions of the proximal and distal duodenum.

Niwa A, Kuwano S, Tomita H, Kimura K, Orihara Y, Kanayama T, Noguchi K, Hisamatsu K, Nakashima T, Hatano Y, Hirata A, Miyazaki T, Kaneko K, Tanaka T, Hara A.

Oncotarget. 2017 Jun 20;8(25):41078-41090. doi: 10.18632/oncotarget.17051.

3.

Atypical Diabetic Foot Ulcer Keratinocyte Protein Signaling Correlates with Impaired Wound Healing.

Hoke GD, Ramos C, Hoke NN, Crossland MC, Shawler LG, Boykin JV.

J Diabetes Res. 2016;2016:1586927. Epub 2016 Oct 20.

4.

Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer.

Stella GM, Gentile A, Balderacchi A, Meloni F, Milan M, Benvenuti S.

J Transl Med. 2016 Sep 2;14:256. doi: 10.1186/s12967-016-1008-4. Review. Erratum in: J Transl Med. 2017 Sep 19;15(1):194.

5.

CD44 regulates Wnt signaling at the level of LRP6.

Orian-Rousseau V, Schmitt M.

Mol Cell Oncol. 2015 Jan 23;2(3):e995046. doi: 10.4161/23723556.2014.995046. eCollection 2015 Jul-Sep.

6.

Ellagitannin-rich cloudberry inhibits hepatocyte growth factor induced cell migration and phosphatidylinositol 3-kinase/AKT activation in colon carcinoma cells and tumors in Min mice.

Pajari AM, Päivärinta E, Paavolainen L, Vaara E, Koivumäki T, Garg R, Heiman-Lindh A, Mutanen M, Marjomäki V, Ridley AJ.

Oncotarget. 2016 Jul 12;7(28):43907-43923. doi: 10.18632/oncotarget.9724.

7.

MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.

Wu S, Wang S, Zheng S, Verhaak R, Koul D, Yung WK.

Mol Cancer Ther. 2016 Jul;15(7):1656-68. doi: 10.1158/1535-7163.MCT-15-0857. Epub 2016 Apr 22.

8.

Biomarker development in MET-targeted therapy.

Zhang Y, Du Z, Zhang M.

Oncotarget. 2016 Jun 14;7(24):37370-37389. doi: 10.18632/oncotarget.8276. Review.

9.

Synaptic Wnt/GSK3β Signaling Hub in Autism.

Caracci MO, Ávila ME, De Ferrari GV.

Neural Plast. 2016;2016:9603751. doi: 10.1155/2016/9603751. Epub 2016 Jan 10. Review.

10.

c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases.

Gayyed MF, Abd El-Maqsoud NM, El-Hameed El-Heeny AA, Mohammed MF.

J Gastrointest Oncol. 2015 Dec;6(6):618-27. doi: 10.3978/j.issn.2078-6891.2015.072.

11.

Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.

Náger M, Santacana M, Bhardwaj D, Valls J, Ferrer I, Nogués P, Cantí C, Herreros J.

Cell Cycle. 2015;14(22):3644-55. doi: 10.1080/15384101.2015.1104443.

12.

Wnt/β-catenin, an oncogenic pathway targeted by H. pylori in gastric carcinogenesis.

Song X, Xin N, Wang W, Zhao C.

Oncotarget. 2015 Nov 3;6(34):35579-88. doi: 10.18632/oncotarget.5758. Review.

13.

Targeted therapy in cancer.

Tsimberidou AM.

Cancer Chemother Pharmacol. 2015 Dec;76(6):1113-32. doi: 10.1007/s00280-015-2861-1. Epub 2015 Sep 21. Review.

14.

MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation.

Chen TT, Filvaroff E, Peng J, Marsters S, Jubb A, Koeppen H, Merchant M, Ashkenazi A.

EBioMedicine. 2015 Mar 28;2(5):406-20. doi: 10.1016/j.ebiom.2015.03.021. eCollection 2015 May.

15.

CD44 Acts as a Signaling Platform Controlling Tumor Progression and Metastasis.

Orian-Rousseau V.

Front Immunol. 2015 Apr 8;6:154. doi: 10.3389/fimmu.2015.00154. eCollection 2015. Review.

16.

Role of HGF/MET axis in resistance of lung cancer to contemporary management.

Raghav KP, Gonzalez-Angulo AM, Blumenschein GR Jr.

Transl Lung Cancer Res. 2012 Sep;1(3):179-93. doi: 10.3978/j.issn.2218-6751.2012.09.04. Review.

17.

HSP105 recruits protein phosphatase 2A to dephosphorylate β-catenin.

Yu N, Kakunda M, Pham V, Lill JR, Du P, Wongchenko M, Yan Y, Firestein R, Huang X.

Mol Cell Biol. 2015 Apr;35(8):1390-400. doi: 10.1128/MCB.01307-14. Epub 2015 Feb 2.

18.

Repurposing the antipsychotic trifluoperazine as an antimetastasis agent.

Pulkoski-Gross A, Li J, Zheng C, Li Y, Ouyang N, Rigas B, Zucker S, Cao J.

Mol Pharmacol. 2015;87(3):501-12. doi: 10.1124/mol.114.096941. Epub 2014 Dec 31.

19.

Implications of targeted genomic disruption of β-catenin in BxPC-3 pancreatic adenocarcinoma cells.

Olsen PA, Solberg NT, Lund K, Vehus T, Gelazauskaite M, Wilson SR, Krauss S.

PLoS One. 2014 Dec 23;9(12):e115496. doi: 10.1371/journal.pone.0115496. eCollection 2014.

20.

Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients.

Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S, Stremitzer S, Yamauchi S, Sebio A, El-khoueiry R, Iqbal S, Barzi A, Gerger A, Stotz M, Azuma M, Watanabe M, Koizumi W, Lenz HJ.

Pharmacogenet Genomics. 2014 Dec;24(12):588-96. doi: 10.1097/FPC.0000000000000091.

Supplemental Content

Support Center